<DOC>
	<DOCNO>NCT01297322</DOCNO>
	<brief_summary>The objective trial demonstrate safety effectiveness Cardiva VASCADE™ Vascular Closure System ( VCS ) seal femoral arterial access site . Hypothesis : The Cardiva VASCADE™ VCS provide time hemostasis ( TTH ) time ambulation ( TTA ) result less manual compression clinically meaningful statistically significant margin . The rate major access site-related complication Cardiva VASCADE™ VCS non-inferior major complication rate manual compression seal femoral arterial access site .</brief_summary>
	<brief_title>RESPECT Trial - ( Rapid Extravascular Sealing Via PercutanEous Collagen ImplanT )</brief_title>
	<detailed_description />
	<criteria>PreOperative Patients undergo elective , nonemergent diagnostic interventional endovascular procedure via common femoral artery use 6 7 Fr introducer sheath PreOperative 1 . Advanced refusal blood transfusion , necessary ; 2 . Active systemic cutaneous infection inflammation ; 3 . Preexisting immunodeficiency disorder and/or chronic use systemic steroid ; 4 . Known , significant history bleed diathesis , coagulopathy , von Willebrand 's disease current platelet count &lt; 100,000 cells/mm3 , baseline INR ≥1.8 , fibrinogen level le 150 mg/dl ( receive fibrinolytic agent within prior 24 hour ) ; 5 . Severe coexist morbidity life expectancy le 30 day ; 6 . Currently involve investigational clinical trial ; 7 . Ipsilateral femoral arteriotomy within previous 30 day ; 8 . Planned endovascular procedure within next 30 day ; 9 . Previous ipsilateral femoral artery closure use permanent implantbased closure device ; 10 . Previous vascular graft surgery target vessel access site ; 11 . History symptomatic peripheral arterial disease , revascularization deep vein thrombosis ipsilateral limb ; 12 . Unilateral bilateral low extremity amputation ( ) ; 13 . Significant anemia hemoglobin level le 10 g/dL hematocrit le 30 % ; 14 . Renal insufficiency ( serum creatinine &gt; 2.5 mg/dl ) ; 15 . Females pregnant , plan become pregnant within 3 month procedure , lactate ; 16 . Extreme morbid obesity ( BMI great 45 kg/m2 ) underweight ( BMI le 20 kg/m2 ) ; 17 . Unable routinely walk least 20 foot without assistance ( see protocol ) ; 18 . Known allergy/adverse reaction bovine derivative , sodium hyaluronate hyaluronan preparation ; 19 . Procedures extend hospitalization ( e.g. , stag endovascular procedure , CABG ) ; 20 . Administration low molecular weight heparin ( LMWH ) within 8 hour procedure . Intraop Exclusion Criteria 1 . An introducer sheath overall length great 11 cm , 6 Fr 7 Fr diameter ; 2 . Femoral artery diameter le 6 mm access site ; 3 . Difficult insertion procedural sheath needle stick problem onset procedure ( e.g. , multiple stick attempt , `` back wall stick '' , etc . ) ; 4 . Angiographic evidence minimal calcium , atherosclerotic disease , stent within 1 cm puncture site ; 5 . Overlapping Common Femoral Vein Femoral Artery access site ; 6 . Placement ipsilateral venous sheath procedure ; 7 . Arterial access site locate common femoral artery ( e.g. , bifurcation , low border inferior epigastric artery , pelvic brim ) ; 8 . More one access site require ; 9 . Loss distal pulse ipsilateral extremity procedure ; 10 . Subjects receive unfractionated heparin ACT great 300 second absence glycoprotein IIb/IIIa inhibitor great 250 second presence glycoprotein IIb/IIIa inhibitor ( may wait remove introducer sheath ACT level reach target value ) ; 11 . Intraprocedural bleed around sheath , suspect intraluminal thrombus , hematoma , pseudoaneurysm , AV fistula ; 12 . Systemic hypertension ( BP great 180/110 mmHg ) hypotension ( BP le 90/60 mmHg ) prior randomization ; 13 . Length tissue tract , distance anterior arterial wall skin , estimate less 2.5 cm ; 14 . If physician deems different method use achieve hemostasis arterial site subject attempt ambulation accord protocol requirement .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>vascular closure system</keyword>
	<keyword>manual compression</keyword>
	<keyword>femoral arteriotomy</keyword>
	<keyword>percutaneous endovascular procedure</keyword>
</DOC>